Journal Mobile Options
Table of Contents
Vol. 48, No. 2, 2003
Issue release date: September 2003
Neuropsychobiology 2003;48:82–86
(DOI:10.1159/000072882)

Gabapentin versus Ropinirole in the Treatment of Idiopathic Restless Legs Syndrome

Happe S. · Sauter C. · Klösch G. · Saletu B. · Zeitlhofer J.
Departments of aClinical Neurology and bPsychiatry, University of Vienna, Vienna, Austria; cDepartment of Clinical Neurophysiology, University of Göttingen, Göttingen, Germany

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Dopaminergic agents such as ropinirole are the drugs of first choice in treating restless legs syndrome (RLS). Recently, gabapentin, a structural analogue of γ-aminobutyric acid, has also been shown to improve sensorimotor symptoms in RLS. Therefore, the tolerability and efficacy of randomized treatment with either gabapentin or ropinirole in patients with idiopathic RLS was evaluated in this 4-week open clinical trial. Patients with idiopathic RLS were treated with either 300 mg of gabapentin (n = 8) or 0.5 mg of ropinirole (n = 8) as the initial dose, and the dose was up-titrated until relief of symptoms was achieved (gabapentin mean dosage 800 ± 397 mg, range 300–1,200 mg; ropinirole mean dosage 0.78 ± 0.47 mg, range 0.25–1.50 mg). In both groups, International Restless Legs Syndrome Study Group questionnaire scores improved significantly (p ≤ 0.018), whereas the scores of the Epworth sleepiness scale remained unchanged within normal limits. Polysomnographic data showed a reduction of periodic leg movements during sleep (PLMS; p < 0.03) and PLMS index (p < 0.02) in both groups. Side effects were only mild and mostly transient. After 6–10 months of follow-up, in most patients, RLS symptoms were still improved. We conclude that gabapentin and ropinirole provide a similarly well-tolerated and effective treatment of PLMS and sensorimotor symptoms in patients with idiopathic RLS.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Rothdach AJ, Trenkwalder C, Haberstock J, Keil U, Berger K: Prevalence and risk factors of RLS in an elderly population: The MEMO study. Memory and morbidity in Augsburg elderly. Neurology 2000;54:1064–1068.
  2. Walters AS: Toward a better definition of the restless legs syndrome. The International Restless Legs Syndrome Study Group. Mov Disord 1995;10:634–642.
  3. Montplaisir J, Boucher S, Poirier G, Lavigne G, Lapierre O, Lesperance P: Clinical, polysomnographic and genetic characteristics of restless legs syndrome: A study of 133 patients diagnosed with new standard criteria. Mov Disord 1997;12:61–65.
  4. Chesson AL, Wise M, Davila D, Johnson S, Littner M, Anderson WM, Hartse K, Rafecas J: Practice parameters for the treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine Report. Standards of Practice Committee of the Academy of Sleep Medicine. Sleep 1999;22:961–968.
  5. Hening W, Allen R, Earley C, Kushida C, Picchietti D, Silber M: The treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine review. Sleep 1999;22:970–999.
  6. Ondo W: Ropinirole for restless legs syndrome. Mov Disord 1999;14:138–140.
  7. Freeman A, Rye DB, Bliwise D, Chokroverty S, Krulewicz S, Watts RL: Ropinirole for the restless legs syndrome (RLS). An open-label and double-blind placebo-controlled study (abstract). Neurology 2001;56(suppl 3):A5.
  8. Saletu B, Gruber G, Saletu M, Brandstatter N, Hauer C, Prause W, Ritter K, Saletu-Zyhlarz G: Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 1. Findings on objective and subjective sleep and awakening quality. Neuropsychobiology 2000;41:181–189.
  9. Saletu M, Anderer P, Saletu B, Hauer C, Mandl M, Oberndorfer S, Zoghlami A, Saletu-Zyhlarz G: Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 2. Findings on periodic leg movements, arousals and respiratory variables. Neuropsychobiology 2000;41:190–199.
  10. Mellick GA, Mellick LB: Management of restless legs syndrome with gabapentin (Neurontin) (letter). Sleep 1996;19:224–226.
  11. Adler CH: Treatment of restless legs syndrome with gabapentin. Clin Neuropharmacol 1997;20:148–151.
  12. Happe S, Klösch G, Saletu B, Zeitlhofer J: Treatment of idiopathic restless legs syndrome (RLS) with gabapentin. Neurology 2001;57:1717–1719.
  13. Garcia-Borreguero D, Larrosa O, de la Llave Y, Verger K, Masramon X, Hernandez G: Treatment of restless legs syndrome with gabapentin. A double-blind, cross-over study. Neurology 2002;59:1573–1579.
  14. Walters AS: Toward a better definition of restless legs syndrome. The International Restless Legs Syndrome Study Group. Mov Disord 1995;10:634–642.
  15. Rechtschaffen A, Kales A: A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects. Washington, Public Health Service, US Government Printing Office, 1968.
  16. Becker PM, Ondo W, Sharon D: Encouraging initial response of restless legs syndrome to pramipexole. Neurology 1998;51:1221–1223.
  17. Bloch KE, Schoch OD, Zhang JN, Russi EW: German version of the Epworth Sleepiness Scale. Respiration 1999;66:440–447.
  18. Mezzich JE, Cohen NL, Ruipiérez MA: A quality of life index. Brief description and validation (abstract). Congress of the International Federation for Psychiatric Epidemiology, Santiago de Compostela, 1996.
  19. Mezzich JE, Ruiperez MA, Perez C, Yoon G, Liu J, Mahmud S: The Spanish version of the quality of life index: Presentation and validation. J Nerv Ment Dis 2000;188:301–305.
  20. Saletu B, Prause W, Löffler-Stastka H, Anderer P, Brandstätter N, Zoghlami A, Saletu-Zyhlarz G, Katschnig H: Quality of life in nonorganic and organic sleep disorders. I. Comparison with normative data. Wien Klin Wochenschr 2003;115:246–254.
  21. Buysse DJ, Reynolds CF 3rd, Monks TH, Berman SR, Kupfer DJ: The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193–213.
  22. Zung WWK: A self-rating depression scale. Arch Gen Psychiatry 1965;12:63–70.
  23. Zung WWK: A rating instrument for anxiety disorders. Psychosomatics 1971;12:371–379.
  24. Suman-Chauhan N, Hill DR, Woodruff GN: Characterization of [3H]gabapentin binding to a novel site in rat brain: Homogenate binding studies. Eur J Pharmacol 1993;244:293–301.
  25. Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S: Falling asleep at the wheel: Motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999;52:1908–1910.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50